Heart failure with preserved ejection fraction
Conditions
Interventions
Prescription of SacbitrilValsaltan and Dapagliflogin in addition to other heart failure treatment
No medication or heart failure medications other than sacubitril valsartan and dapagliflozin
Sponsors
Kansai Rosai Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients must be free of AF recurrence at 6 months after the last catheter ablation for paroxysmal or persistent AF and have chronic heart failure.
Exclusion criteria
Exclusion criteria: Patients with left ventricular ejection fraction < 50%, prior cardiac surgery, unstable heart failure, patients under 20 years of age or of childbearing potential, patients already taking sacubitril valsartan and dapagliflozin, and patients who are judged by the attending physician to be difficult to use heart failure drugs in this study Patients with hypotension with systolic blood pressure < 100 mmHg, renal dysfunction with eGFR < 30 mL/min/1.73 m2 or creatinine clearance < 30 mL/min, hyperkalemia with potassium level > 5.0 mEq/L, diabetes requiring insulin injection or oral hypoglycemic agents), and Other cases deemed inappropriate by the attending physician
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| (1) Change in left atrial strain (reservoir strain, conduit strain, contractile strain) at 6 months after enrollment Composite endpoint consisting of all-cause mortality and heart failure hospitalization at 6 months after enrollment | — |
Countries
Japan
Contacts
Public ContactMasaharu Masuda
Kansai Rosai Hospital Cardiovascular center
Outcome results
None listed